Publications
Effectiveness and safety of bedaquiline-based, modified all-oral 9-11-month treatment regimen for rifampicin-resistant tuberculosis in Vietnam Institute of Tropical Medicine
World Health Organization recommends a 7-drug 9–11-month rifampicin-resistant tuberculosis (RR-TB) short treatment regimen (STR). To reduce the pill burden, we assessed the safety and effectiveness of a 5-drug 9–11-month modified STR (mSTR).
Methods
Prospective cohort study of an all-oral mSTR (comprising bedaquiline, levofloxacin, linezolid [LZD], clofazimine, and/or pyrazinamide) for patients with RR-TB ...
MDACT : a new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs, with an example regimen Ghent University
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries Institute of Tropical Medicine
SETTING: Nine countries in West and Central Africa.
OBJECTIVE : To assess outcomes and adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB) among patients never previously treated with second-line drugs.
DESIGN: Prospective observational study of MDR-TB patients treated with a standardised 9-month regimen including moxifloxacin, clofazimine, ethambutol (EMB) and ...
A 6 week quadruple drug regimen for the treatment of multibacillary leprosy Institute of Tropical Medicine
Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: a retrospective cohort stud Institute of Tropical Medicine
SETTING: Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regimen was used to treat MDR-TB.
OBJECTIVES: In a post-Ebola context, with a weakened health system, we describe the MDR-TB treatment uptake, patients ...
Principles for constructing a tuberculosis treatment regimen Institute of Tropical Medicine
Current World Health Organization guidelines for the formulation of treatment regimens for multidrug-resistant tuberculosis (MDR-TB) pay too little attention to the microbiological activity of anti-tuberculosis drugs. Here, we draw lessons from the pioneering work done on shorter MDR-TB treatment regimens and the current knowledge of the bactericidal and sterilizing properties of the drugs to inform the composition of treatment regimens for ...
Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen University of Antwerp Institute of Tropical Medicine
Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes Institute of Tropical Medicine
Background
Since a meta-analysis showed little or no effect of second-line injectables on treatment success, and using injectables may induce ototoxicity, injectable-free rifampicin-resistant tuberculosis (RR-TB) treatment regimens are recommended. However, acquired resistance preventing activity was overlooked. No previous study assessed the effect of shortening the duration of kanamycin administration to 2 months during the ...